Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

NEWS FEEDS

Does The Work Of The National Institute For Health And Clinical Excellence (NICE) Have Any Relevance For The United States?

The growing emphasis on evidence-based decision-making in health care, especially regarding health technologies, has generated notable debate and discussion in the U.S. around establishing a more formalized process or system for conducting comparative effectiveness research. In the eyes of many observers, this is quite similar to the health technology assessment programs existing in a number of European countries. The National Institute for Health and Clinical Excellence (NICE) in the U.K. is one the most discussed and debated systems currently in operation, since it represents one of the most sophisticated national attempts to systematically review the value, or relative costs and benefits, of various treatments. The National Pharmaceutical Council commissioned a study of NICE in order to understand its methods of working and to explore its relevance to the United States.

Blog Post

CER Tweets of the Week: All Things Patient (August 11-15)

This week’s comparative effectiveness research (CER) tweets revolve around patient-centric news. The Patient-Centered Outcomes Research Institute’s (...
Blog Post

CER Tweets of the Week: Will CER Really Deliver Better Patient Outcomes? (August 4-8)

Comparative effectiveness research (CER) stakeholders shared news about the Patient-Centered Outcomes Research Institute’s next funding round with...
Newsletter Volume

E.V.I.dently July 2014

NPC MessageWhen & How Health Decision-Makers Should Consider Individual Patient DifferencesBy Jennifer S. Graff, PharmD, NPC Director of...
Blog Post

PCORI Grants, HEOR & FDA Guidance Top CER Tweets of the Week (July 21-25)

What were some of the popular comparative effectiveness research (CER)-related topics on Twitter this week? We saw keen interest in the Patient-...
Press Release

NPC Study Outlines When & How Health Decision-Makers Should Consider Individual Patient Differences

Washington, DC (July 29, 2014)—New research led by the National Pharmaceutical Council (NPC) can assist health care stakeholders to understand when...
Press Release

NPC Annual Stakeholder Survey: Comparative Effectiveness Research Is Important, But Impact on Health Care Decision-Making Is Still on the Horizon

(Washington, DC, May 19, 2014)—A new survey of health care stakeholders reveals continued optimism for the use of comparative effectiveness research...
Press Release

CER Collaborative Improving Health Outcomes Through New Comparative Evidence Tools

(Washington, DC, March 24, 2014)—Three peer-reviewed articles published in Value in Health offer important guidance to aid formulary decision-makers...
Press Release

NPC, UMD Study: Factors That Cause Different Treatment Responses Are Not Well Understood or Studied

Washington, DC, November 4, 2013—Although researchers and health care providers widely recognize that individuals with stage IV prostate cancer react...
Commentary and Testimony Page

The State of CER and the Environment for Health Care Decision Making

This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (CER), “The State of Comparative...
Commentary and Testimony Page

Keeping Our Eye on the CER Ball

Until the cherry blossoms begin to bloom later next month, most of the water cooler conversations in Washington will focus on the federal budget....
Commentary and Testimony Page

Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?

A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...
Commentary and Testimony Page

Living Up to Its Name? The Role of Patient-Centered Research

Anyone who has ever received bad news from his or her health care provider or held a loved one’s hand when a diagnosis was delivered can understand...
YouTube Videos

Differences in Global Health Technology Assessment

David Grainger, senior director, global public policy, Eli Lilly and Company, describes how health technology assessment (HTA) informs policy and...
YouTube Videos

Incorporating Patient Views Into Health Technology Assessments

David Grainger, senior director, global public policy, Eli Lilly and Company, explains that many health technology assessments are incorporating...
YouTube Videos

Health Technology Assessments and Specialty Medications

David Grainger, senior director, global public policy, Eli Lilly and Company, says that there are often challenges in conducting health technology...
YouTube Videos

Real-World Impact of Comparative Effectiveness Research Findings on Clinical Practice

National Pharmaceutical Council Chief Science Officer Robert W. Dubois, MD, PhD, discusses a peer-reviewed study suggesting that changes are needed...
Blog Post

CER Tweets of the Week: All Things Patient (August 11-15)

This week’s comparative effectiveness research (CER) tweets revolve around patient-centric news. The Patient-Centered Outcomes Research Institute’s (...
Blog Post

CER Tweets of the Week: Will CER Really Deliver Better Patient Outcomes? (August 4-8)

Comparative effectiveness research (CER) stakeholders shared news about the Patient-Centered Outcomes Research Institute’s next funding round with...
Blog Post

PCORI Grants, HEOR & FDA Guidance Top CER Tweets of the Week (July 21-25)

What were some of the popular comparative effectiveness research (CER)-related topics on Twitter this week? We saw keen interest in the Patient-...
Blog Post

#TBT: Expanding Your Horizons: CER Continuing Education Certificate Program

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...

Research

  •  
  • 1 of 41
  • >

Commentary & Testimony